Kathryn Jones

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi et al. · The Lancet · 2020 · 5K citations · Full text

Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial

Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley et al. · The Lancet · 2020 · 2.6K citations · Full text

Vaccination, Vaccine Safety, Phase 1/2 +7

Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials

Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi et al. · The Lancet · 2021 · 1.2K citations · Full text

Sarafotoxin S6c: An agonist which distinguishes between endothelin receptor subtypes

David L. Williams, Kathryn Jones, Douglas J. Pettibone et al. · Biochemical and Biophysical Research Communications · 1991 · 384 citations

Molecular Pharmacology, Sarafotoxin S6c, Molecular Physiology +4

Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies

Wilton B. Williams, Hua-Xin Liao, M. Anthony Moody et al. · Science · 2015 · 202 citations